Strong Execution and Milestones
Achieved a key milestone in the petrelintide Phase II ZUPREME-1 trial in obesity. Rapidly approaching data from several Phase III trials with survodutide in obesity.
Financial Performance and Position
Revenue for the first 9 months of 2025 was DKK 9.1 billion, primarily from the initial upfront payment from Roche. Cash position increased to DKK 16.2 billion as of September 30, 2025.
Partnerships and Collaborations
Continued momentum in the partnership with Roche. Positive engagement with Boehringer Ingelheim in obesity management.
Pipeline Advancements
Phase III SYNCHRONIZE program of survodutide in obesity consists of 6 trials expected to complete in 2026. Encouraged by the clinical profile of glepaglutide for short bowel syndrome.